IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): McCormick_et

Serial No.: 09/539,38

Filed: 3/31/2000

Title: Self Antigen Vaccines for Treating B-

JAN 1 1 2003

Cell Lymphomas and Other Cancers

Attorney Docket No.: 42204

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Group Art Unit: 1642

Examiner: YAEN, Christopher H.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted under 37 CFR 1.97(c) together with a \$180.00 fee under 37 CFR 1.17(p).

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit:

Typed Name: Thomas Gallegos

Respectfully submitted,

Thomas Gallegos, Reg. No. 32,692 Attorney/Agent for Applicant(s)

Telephone No. (707) 469-2307

CINENESS HOUTERAS GCCCGCCC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

106	Complete if Known		
FEE TRANSMIT TO LET	Application Number	09/539,382	
/ %	Filing Date	3/31/2000	
for FY 2004 JAN 1 1 2005	First Named Inventor	McCormick, et al.	
Effective 10/01/2003. Patent fees are subject to altigral revision.	Examiner Name	YAEN, Christopher H.	
X Applicant Claims small entity status. See 37 127 127	Art Unit	1642	
TOTAL AMOUNT OF PAYMENT (\$) 180.00	Attorney Docket No.	42204	
	<u> </u>		

METHOD OF PAYMENT (check all that apply)				FE	E CALCULATION (continued)	
Charle Craft and Maney Other None	3 A	OITIO	NAL F	EES		
	Large	Entity	Small	Entity		
	Code	/\$)	Code	/ee (\$)	Fee Description	Fee Paid
Deposit Account Support	1051	130	2051	65	Surcharge – late filing fee or oath	
Deposit Account Name	1052	50	2052	25	Surcharge – late provisional filing fee or cover sheet	
The Director is authorized to: (check all that apply)	1053	130	1053	130	Non-English specification	
Check Credit card Money Other None X Deposit Account Sposit Sposit						
Check				920*	Requesting publication of SIR prior to	
Charge fee(s) indicated below, except for the filing fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after	
to the above-identified deposit account.	1				Examiner action	
FEE CALCULATION	1251	110	2251	55	Extension for reply within first month	
1. BASIC FILING FEE	1252	430	2252	215	Extension for reply within second month	
Large Entity Small Entity	1253	980	2253	490	Extension for reply within third month	
Fee Fee Fee Fee Description Fee Paid	1254	1,530	2254	765	Extension for reply within fourth month	
(1)	1255	2,080	2255	1,040	Extension for reply within fifth month	
,	1401	340	2401	170	Notice of Appeal	
	1402	340	2402	170	Filing a brief in support of an appeal	
	1403	300	2403	150	Request for oral hearing	
	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
	1452	110	2452	55	Petition to revive – unavoidable	
SUBTOTAL (1) (\$)	1453	1,370	2453	685	Petition to revive – unintentional	
	2501	685	Utility issue fee (or reissue)			
Total Claims	1503	660	2503	330	Plant issue fee	
Independent Same X = X	1460	130	1460	130	Petitions to the Commissioner	
Multiple Dependent =	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
	1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
	8021	40	8021	40		
1202 18 2202 9 Claims in excess of 20	1809	790	2809	395		
1201 88 2201 44 Independent claims in excess of 3	1810	790	2810	395		
1203 300 2203 150 Multiple dependent claim, if not paid	1801	790	2801	395	• • •	
1204 88 2204 44 **Reissue independent claims over original patent	1802	900	1802	900		
1205 18 2205 9 **Reissue claims in excess of 20			•			
SUBTOTAL (2) (\$)	Other	fee (spe	cify)			
•• or number previously paid, if greater, For Reissues, see above	*Redu	ced by Bas	sic Filing	Fee Paid	SUBTOTAL (3) (\$) 180.	00

SUBMITTED BY		Complete (il	applicable)		
Name (Print/Type)	Thomas Gallegos	Registration No. (Attorney/Agent)	32,692	Telephone	(707) 469-2307
Signature	Thung Cult	2		Date	70m 2005

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0331 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

42204

required to Under the Paperwork Reduction Act of 1995, no personal respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for form 1449A/PTO JAN ! 1 2005 09/539,382 Application Number SUPPLEMENTA Filing Date 3/31/2000 INFORMATION DISCLÖSURE First Named Inventor McCormick et al. STATEMENT BY APPLICANT Art Unit 1642 (Use as many sheets as necessary) **Examiner Name** Yaen, Christopher H.

Attorney Docket Number

			U.S. PATENT	DOCUMENTS		
	011	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Examiner Cite Initials* No.	No.1	Number - Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		0				

2

1

Sheet

FOREIGN PATENT DOCUMENTS						
Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
	WO 94/08008	4/14/1994	HAWKINS, et al.			
		Cite No. Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Cite No. 1 Country Code 3 - Number 4 - Kind Code 5 (if known) Publication Date MM-DD-YYYY	Cite No. 1 Country Code 3 - Number 4 - Kind Code 5 (if known) Foreign Patent Document Publication Date MM-DD-YYYY Applicant of Cited Document	Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages Ocuntry Code ³ - Number ⁴ - Kind Code ⁵ (if known) Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages Ocuntry Code ³ - Number ⁴ - Kind Code ⁵ (if known) Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages Ocuntry Code ³ - Number ⁴ - Kind Code ⁵ (if known) Name of Patentee or Name	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BENVENUTI and BURRONE, "Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V _L /V _H determinants", <i>Gene Therapy</i> (2001) 8:1555-1561	
		DE GRUIJL and CURIEL, "Cancer vaccine stategies get bigger and better", <i>Nature Medicine</i> (1999) 5(10):1124-1125	
		DONNELLY, "Cancer vaccine targets leukemia", <i>Nature Medicine</i> (2003) 9(11):1354-1356	
		FIEDLER, et al., "Optimization of scFv antibody production in transgenic plants", Immunotechnology (1997) 3:205-216	
		HAKIM, et al., "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines", <i>J. Immun.</i> (1996) 157(12):5503-5511	
		HENNECKE, et al., "Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology", <i>Protein Engineering</i> (1998) 11(5):405-410	
		HSU, et al., "Tumor-Specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial", <i>Blood</i> (1997) 89(9):3129-3135	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Under ti	ne Paperwork Reduction Act of 1995, n	o persor	QIP of the res		red for use through 07/31/2006. OMB 0651-003 Mark Office; U.S. DEPARTMENT OF COMMERCE on unless it displays a valid OMB control number
Sub	stitute for form 1449A/PTO	7	813	Coi	mplete if Known
	SUPPLEMENT		N 1 1 2005	Application Number	09/539,382
AI.	SOFFELIALIA I	700	HDE &	Filing Date	3/31/2000
111	SUPPLEMENTA IFORMATION DISCI TATEMENT BY APF		A 10EM	First Named Inventor	McCormick et al.
)	IAIEWENI DI APP	LIC	AN	Art Unit	1642
	(Use as many sheets as nece	ssary)		Examiner Name	Yaen, Christopher H.
Sheet	2	of	2	Attorney Docket Number	42204

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		STEMMER, et al., "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR", <i>Biotech</i> . (1993) 14(2):256-265	
36		TAVLADORAKI, et al., "A single-chain antibody fragment is functionally expressed in the cytoplasm of both <i>Escherichia coli</i> and transgenic plants", <i>European J. Biochem.</i> (1999) 262(2):617-624	
		TURNER, et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology", <i>J. Immun. Methods</i> (1997) 205(1):43-54	
Examiner		Date	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Signature

Considered

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.